• 검색 결과가 없습니다.

혈액질환 동반없이 난소에 발생한 원발성 과립세포육종 1예 Primary Granulocytic sarcoma of Ovary

N/A
N/A
Protected

Academic year: 2022

Share "혈액질환 동반없이 난소에 발생한 원발성 과립세포육종 1예 Primary Granulocytic sarcoma of Ovary"

Copied!
1
0
0

로드 중.... (전체 텍스트 보기)

전체 글

(1)

-S 880 -

― S-267 ―

혈액질환 동반없이 난소에 발생한 원발성 과립세포육종 1예 Primary Granulocytic sarcoma of Ovary

고신대학교 의과대학 내과학교실

*정수현, 이호섭

배경: 과립세포육종(Granulocytic sarcoma)은 골수모구 또는 미성숙 골수양 세포의 골수외 증식으로 인한 드문 악성종양으로 어느 조직이나 침범이 가능하나 주로 피부, 뼈, 눈의 연부조직, 림프절에 많이 발생하며 여성생식기의 경우 난소와 자궁에 호발한다. 대부분 급성 골수성 백혈병과 동반되어 발생하나 드물게 동반된 혈액질환 없이 원발성으로 발생하기도 하며 이경우 수개월내 급성 골수성 백혈병으로 진행한다.

골수성 백혈병 환자에서의 난소 침범은 흔히 보고되고 있으나 원발성으로 난소에 발생하는 과립세포육종은 매우 드문 것으로 알려져 있으며 저자들은 혈액 질환의 동반없이 난소에서 발생한 과립세포육종 1예를 경험하였기에 보고하는 바이다. 증례: 37세 여자가 2일간의 하복부 통증을 주소로 내원하였다. 입원당시 신체검진상 창백한 결막을 보였으며 골반진찰시 자궁이 임신5개월 크기로 커져있었다. 검사실소견상 말초백혈구 3800/mm3(중성구53.8%,임파구31.8%,단핵구11.2%),혈색소 8.6gm/이,혈소판 317000/mm3이었고 복부 전산화단층촬영상 11cm가 량 비교적 둥근 골반내 종괴소견 보였다. 2009년 5월 12일 골반내 종괴 제거위한 수술 시행하였으며 좌측난소에 13cm 크기의 불규칙한 모 습의 종괴가 염전되어있었으며 육안상 capsule은 보존된 상태였다. 우측난소는 정상소견 보였으며 자궁 역시 정상크기로 확인되었다. 좌측난 소의 악성종양으로 생각되어 전자궁 적출술및 양측 부속기절제술, 대망 절제술, 양측 골반내 임파선곽청술, 충수 돌기절제술 시행하였다.

술후 조직 면역조직화학분석검사상 myeloperoxidas와 lysosome 염색에 양성보이는 미분화된 과립세포 육종 진단되었고 주변임파선 모두 종 양세포의 침범은 없었다.골수검사상 Blast 1.7%로 정상 골수보였으며 골조직검사상 Normocellular marrow소견 보였다. 염색체 검사상 46.XX 확인되었으며 형광동소보합법(Fluorescence in Situ Hybridization)상 혈액질환 유전자 모두 음성으로 확인되었다. 전신 침범여부 확인위해 전 산화단층촬영, 상하부위장관촬영, 양전자방출단층촬영 시행하였으며 모두 종양의 침범은 관찰되지 않았다. 이에 저자들은 선행하는 혈액질 환없이 발병한 난소에 국한된 원발성 과립세포육종이라 진단하고 급성 골수성 백혈병에 준하여 관해 유도 항암치료로 시타라빈 (cytarabine,100 mg/m2)과 다우노루비신 (daunorubicin,50 mg/m2)을 각각 7일및 3일간 투여하였으며 현재는 관해후 강화요법으로 고용량 시 타라빈(cytarabine,3g/m2)투여중이며 특별한 합병증없이 경과 관찰중에 있다.

― ♣S-268 ―

Relapsed marginal zone B-cell lymphoma: Clinical features and treatment outcome

1Dong-A University College of Medicine, 2Samsung Medical Center, 3Yonsei University College of Medicine, 4Asan Medical Center, 5Soon Chun Hyang University, 6Chung-Ang University Young San Hospital, 7Yeungnam University College of Medicine, 8Dankook University College of Medicine, 9Kyungpook National University School of Medicine, 10Chonnam National University Hwasun Hospital, 11Korea Cancer Center Hospital,

12Korea University Anam Hospital, 13Gachon Medical School, 14Pusan National University Hospital, 15Hallym University College of Medicine

*Sung Yong Oh1, Won Seog Kim2, Seok Jin Kim2, Jin Seok Kim3, Sung-Hyun Kim1, Dae Ho Lee4, Jong Ho Won5, In Gyu Hwang6, Min Kyoung Kim7, Soon Il Lee8, Jong Gwang Kim9, Deok-Hwan Yang10, Hye Jin Kang11, Chul Won Choi12, Jinny Park13, Young Jin, Choi14,

Hyo Jung Kim15, Jung Hye Kwon15, Cheolwon Suh4 and Hyo-Jin Kim1

Background: Marginal zone B-cell lymphoma (MZL) has an indolent clinical course and long survival. During its long survival duration, MZL has tendency to relapse frequently. But the natural history and an optimal treatment modality for relapsed MZL has yet to be well established.

So we performed a retrospective analysis of identifying the clinical features and outcomes of relapsed MZL. Methods: From 1994 to 2008, a total of 92 patients with relapsed MZL were analyzed retrospectively. Results: The median age of our subjects was 53.5 years (range: 23-82 years). This study involved 51 males (55.4%) and 41 females (44.6%). The most common primary sites of involvement were orbit and ocular adnexa (28.3%) followed by lymph node and lymphatic organs (23.9%), and multiple MALT sites (13.0%). The median time to relapse from initial diagnosis was 25.5 months (range: 1.6- 137 months). Of the 53 patients with stage I or II at diagnosis, 42 patients (79.2%) had been shown the loco-regional recurrence. Among these loco-regional relapsed patients, 27 patients were achieved CR (54.1%) or PR (18.9%). The other 11 patients (20.8%) had advanced stage at recurrence. Adding to 39 patients initially advanced stage III or IV, totally 50 patients were advanced stage at relapse. Of these patients with advanced stage at relapse, 44 patients had been treated. The overall response rate was 54.5%

(24 patients), with 18 CRs and 6 PRs. The median time to progression (TTP) was 34.1 months (95% CI: 11.3-56.9 months) and the estimated 5-year OS was 84.3%. Conclusion: Loco-regional recurrence was more dominant than distant metastases in stage I or II MZL regardless of treatment modality. Even though patients had relapsed MZL after initial treatment, most of them were well controlled with salvage treatment and could achieve prolong survival.

참조

관련 문서

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for

Serum BMP-2 Up-regulation as an Indicator of Poor Survival in Advanced Non-small Cell Lung Cancer Patients studies suggested that disease stage or the number of.. metastatic

The positive expression rates of both KAI1/CD82 and MRP1/CD9 in patients with TNM stage III-V, poorly differentiated, clinical stage III-IV, and metastatic LSCC was

Among the 692 patients who started first-line palliative chemo- therapy for recurrent or primary metastatic gastric cancer at our institution, 23 patients who were transferred

Next, each MBC case was matched with female breast cancer patients who had at least 7 characteristics in common that are relevant for prognosis: age (within  5 years),

Patients with high-risk International Prognostic Score was not associated with worse overall survival (c) in patients with limited-stage classical Hodgkin’s lymphoma,

Controls were selected from the cohort of patients with SLE who were at a risk of developing an infection at the time infection occurred in some patients; each control had to

In conclusion, at 1 year off treatment the virological relapse de- veloped in 73.3% of patients receiving NUC treatment and clinical relapse developed in 53.3% of NUC